Ovarian cancer continues to be a major cause of morbidity and mortality in women.
Antiangiogenic treatments have emerged as a promising strategy to treat ovarian cancer …

Epithelial ovarian cancer is a leading cause of cancer-related death for women both in the
United States and worldwide, and the effectiveness of cytotoxic chemotherapy has …

Angiogenesis plays a pivotal role in normal ovarian physiology as well as in the formation
and progression of ovarian cancer. Several well-designed phase II and III trials studied the …

Ovarian cancer presents at advanced stage in around 75% of women, and despite
improvements in treatments such as chemotherapy, the 5-year survival from the disease in …

Angiogenesis is known to play an important role in normal ovarian physiology as well as in
growth and progression of ovarian cancer. The first FDA approval of bevacizumab in 2004 …

First-line chemotherapy fails in more than 20% of patients with epithelial ovarian cancer and
about 40–50% of women who respond to initial treatment relapse within 2 years. In the …

Angiogenesis is one of the hallmarks of cancer and plays a crucial role in carcinogenesis
and progression of epithelial ovarian cancer. Antiangiogenic agent is the first approved …

Background Many women with ovarian cancer eventually develop resistance to
conventional chemotherapy drugs, and so novel agents are being developed to target …

Introduction: Patients with epithelial ovarian cancer (EOC) have a high rate of recurrence,
and overall survival remains at∼ 25%. There is a need for new treatments that can increase …

The treatment of ovarian cancer remains challenging as the majority of patients will relapse
and die from their disease despite successful first-line treatment. New treatment strategies …